Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Caregiving

Topic: Risk, prevention and care in population studies

Plain-language summary

Results The total cost of disorders of the brain was estimated at €798 billion in 2010. Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with patients' production losses. It should be noted that the revised estimate of those disorders included in the previous 2004 report constituted €477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004. Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe.

What this study adds

Evidence grade: High

This is a pooled review. This study estimated the total cost of brain disorders in Europe, including dementia. It provides economic information for planning but does not test any treatment or prevention for Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., et al. (2011). Cost of disorders of the brain in Europe 2010. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2011.08.008

Vancouver

Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2011. doi:10.1016/j.euroneuro.2011.08.008. PMID: 21924589.

BibTeX

@article{gustavsson2011-21924589,
  author  = {Gustavsson, A. and Svensson, M. and Jacobi, F. and Allgulander, C. and Alonso, J. and Beghi, E. and Dodel, R. and Ekman, M. and others},
  title   = {{Cost of disorders of the brain in Europe 2010}},
  journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  year    = {2011},
  doi     = {10.1016/j.euroneuro.2011.08.008},
  pmid    = {21924589},
  url     = {https://doi.org/10.1016/j.euroneuro.2011.08.008}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study estimated the total cost of brain disorders in Europe, including dementia. It provides economic information for planning but does not test any treatment or prevention for Alzheimer's.

Study details

How this study scored 72/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 72 of 100.72 of 100 points earned28 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology)
Journal's citation record 2 / 4 European Neuropsychopharmacology: journal h-index 158 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 7 / 7 Cited 1,724 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 101.4 citations a year over 17 year(s) since 2011
Impact for its field and year 6 / 6 Cited 140.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 3 / 4 Cited 172 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Jes Olesen: h-index 138 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 38 institution(s) in 14 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21924589)
Free to read 0 / 2 Behind a paywall — scores zero
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Caregiving from nearby years

Also in Caregiving

69 studies in the library are filed under Caregiving with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Caregiving hub.

Similar studies

More on Caregiving

See all studies in Caregiving →